Matthew C Riddle Selected Research

Insulins

1/2018	Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).
12/2015	New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
8/2007	Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
5/2005	Making the transition from oral to insulin therapy.
3/2005	Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations.
2/2004	Timely initiation of basal insulin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew C Riddle Research Topics

Disease

55	Type 2 Diabetes Mellitus (MODY) 01/2022 - 02/2002
20	Hypoglycemia (Reactive Hypoglycemia) 01/2021 - 11/2003
11	Heart Failure 01/2022 - 07/2012
9	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 06/2007
9	Weight Gain 03/2017 - 09/2002
7	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 09/2011
7	Hyperglycemia 11/2018 - 02/2004
6	Stroke (Strokes) 01/2022 - 12/2015
6	Acute Coronary Syndrome 01/2022 - 05/2015
5	Body Weight (Weight, Body) 01/2021 - 11/2006
4	Myocardial Infarction 01/2021 - 07/2012
3	Unstable Angina 11/2020 - 12/2015
3	Glucose Intolerance 07/2012 - 01/2008
2	Hypotension (Low Blood Pressure) 01/2021 - 01/2021
2	Albuminuria 01/2021 - 01/2021
2	Diarrhea 01/2021 - 01/2021
2	Insulin Resistance 01/2018 - 09/2002
2	Neoplasms (Cancer) 01/2014 - 07/2012
2	Weight Loss (Weight Reduction) 08/2013 - 05/2005
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022
1	Chronic Renal Insufficiency 01/2021
1	Infections 01/2021
1	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2021
1	Acute Kidney Injury (Acute Renal Failure) 01/2021
1	COVID-19 10/2020
1	Cognitive Dysfunction 01/2020
1	Ischemic Stroke 01/2020
1	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2018
1	Hypersensitivity (Allergy) 12/2015
1	Pancreatic Neoplasms (Pancreatic Cancer) 12/2015
1	Pancreatitis 12/2015
1	Nausea 09/2013
1	Vomiting 09/2013
1	Cardiac Arrhythmias (Arrythmia) 07/2012
1	Pre-Eclampsia (Preeclampsia) 01/2012
1	Birth Weight (Birth Weights) 01/2012
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2012
1	Hyperbilirubinemia 01/2012
1	Hypertension (High Blood Pressure) 01/2012
1	Macular Edema 03/2010
1	Overweight 11/2003

Drug/Important Bio-Agent (IBA)

27	Insulin (Novolin)FDA Link 01/2020 - 02/2002
24	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 11/2003
18	Insulin Glargine (Lantus)FDA Link 01/2019 - 11/2003
8	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2020 - 05/2014
7	lixisenatideIBA 01/2022 - 09/2013
7	dulaglutideIBA 01/2021 - 01/2018
7	Metformin (Glucophage)FDA LinkGeneric 09/2014 - 02/2004
6	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2021 - 06/2007
6	InsulinsIBA 01/2018 - 02/2004
5	Glucagon-Like Peptide-1 ReceptorIBA 11/2020 - 09/2013
5	IncretinsIBA 11/2020 - 05/2005
4	Blood Glucose (Blood Sugar)IBA 01/2018 - 09/2011
4	Hypoglycemic Agents (Hypoglycemics)IBA 12/2014 - 03/2005
3	Natriuretic PeptidesIBA 01/2022 - 05/2017
3	omega-Chloroacetophenone (Mace)IBA 01/2022 - 11/2020
3	(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triolIBA 01/2021 - 01/2021
3	pramlintide (Symlin)FDA Link 01/2020 - 03/2017
3	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2014 - 07/2012
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2020
2	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 05/2017
2	Pharmaceutical PreparationsIBA 01/2021 - 09/2014
2	Sodium-Glucose Transport ProteinsIBA 01/2021 - 01/2021
2	Hormones (Hormone)IBA 01/2020 - 11/2018
2	Short-Acting InsulinIBA 10/2016 - 09/2013
2	Exenatide (Byetta)FDA Link 11/2006 - 05/2005
2	Human Isophane Insulin FDA Link 01/2006 - 11/2003
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	CreatinineIBA 01/2021
1	Lipoproteins (Lipoprotein)IBA 01/2021
1	AlbuminsIBA 01/2021
1	oxidized low density lipoproteinIBA 01/2021
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2021
1	SodiumIBA 01/2021
1	CarbohydratesIBA 01/2020
1	Insulin Lispro (Humalog)FDA Link 11/2018
1	Retinaldehyde (Retinal)IBA 01/2018
1	Brain Natriuretic Peptide (Natrecor)FDA Link 05/2017
1	Islet Amyloid PolypeptideIBA 03/2017
1	Glucagon-Like Peptides (Enteroglucagon)IBA 12/2015
1	EstersIBA 07/2012
1	Capsules (Microcapsules)IBA 07/2012
1	2,4-thiazolidinedione (thiazolidinedione)IBA 03/2010
1	ThiazolidinedionesIBA 03/2010
1	Isophane Insulin (NPH Insulin)FDA Link 08/2007
1	Insulin SecretagoguesIBA 06/2007
1	Long-Acting Insulin (Insulin, Long Acting)FDA Link 01/2006

Therapy/Procedure

24	Therapeutics 01/2021 - 02/2002
14	Glycemic Control 01/2021 - 11/2003
3	Subcutaneous Injections 01/2019 - 01/2018
2	Injections 01/2018 - 02/2004
1	Infusion Pumps (Infusion Pump) 11/2018
1	Precision Medicine 06/2013
1	Cesarean Section (Caesarean Section) 01/2012